Journal
GASTROENTEROLOGY CLINICS OF NORTH AMERICA
Volume 46, Issue 4, Pages 689-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.gtc.2017.08.002
Keywords
Inflammatory bowel disease; Crohn disease; Ulcerative colitis; Gut microbiota; Complementary and alternative medicine; NutraCeuticals; Next-generation
Categories
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), Digestive Diseases Research Core Centers program [P30DK097948]
- NIH [DK091222, DK042191, DK055812, DK097948]
Ask authors/readers for more resources
The human gut microbiome exerts a major impact on human health and disease, and therapeutic gut microbiota modulation is now a well advocated strategy in the management of many diseases, including inflammatory bowel disease (IBD). Scientific and clinical evidence in support of complementary and alternative medicine, in targeting intestinal dysbiosis among patients with IBD or other disorders, has increased dramatically over the past years. Delivery of artificial stool replacements for fecal microbiota transplantation (FMT) could provide an effective, safer alternative to that of human donor stool. Nevertheless, optimum timing of FMT administration in IBD remains unexplored, and future investigations are essential.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available